Bangham, M;
Goldstein, R;
Walton, H;
Ledermann, JA;
(2016)
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.
Gynecologic Oncology Reports
, 18
pp. 22-24.
10.1016/j.gore.2016.10.004.
Preview |
Text
Bangham_Olaparib_treatment_BRCA-mutant.pdf - Published Version Download (385kB) | Preview |
Abstract
HIGHLIGHTS: Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer; A clinically significant dose of olaprib is able to penetrate the leptomeninges; Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to olaparib.
| Type: | Article |
|---|---|
| Title: | Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease |
| Location: | Netherlands |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.gore.2016.10.004 |
| Publisher version: | https://doi.org/10.1016/j.gore.2016.10.004 |
| Language: | English |
| Additional information: | Copyright © 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | Ovarian cancer; Brain metastases; Leptomeningeal disease; PARP inhibitor; Olaparib; BRCA mutation |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1529618 |
Archive Staff Only
 |
View Item |
